WEX is developing a new class of non-opioid analgesics. WEX’s lead product, Halneuron®, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain, cancer pain, and other pain indications.
Halneuron® is Tetrodoxin (TTX), a highly selective sodium blocker that binds to the NAv 1.7 to block the transmission of pain signals and relieve pain. Unlike opioids, TTX is not addictive to the user and does not cause typical opioid-like side effects.
WEX has successfully conducted 15 clinical trials with TTX. Over 700 people have been treated with TTX to date. Halneuron® is actively being tested in human clinical trials, and is in the process of preparing for a double-blinded, placebo-controlled Phase 3 trial.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore fugiat sunt culpa officia deserunt mollit anim est laborum.